USS Investment Management Ltd Purchases 915 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Posted by Geri Gentry on Jul 2nd, 2026

USS Investment Management Ltd increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 4.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,230 shares of the biopharmaceutical company’s stock after buying an additional 915 shares during the quarter. USS Investment Management Ltd’s holdings in Regeneron Pharmaceuticals were worth $15,626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC boosted its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $226,000. Arrowstreet Capital Limited Partnership bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at $3,183,000. Gabelli Funds LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after purchasing an additional 55 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Regeneron Pharmaceuticals by 18.8% during the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares during the period. Institutional investors own 83.31% of the company’s stock.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $705.24, for a total transaction of $70,524.00. Following the sale, the director owned 17,503 shares in the company, valued at $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Trading Up 0.2%

REGN opened at $624.72 on Thursday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $529.69 and a twelve month high of $821.11. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $656.18 and a 200-day moving average of $726.61. The stock has a market cap of $66.05 billion, a PE ratio of 15.22, a price-to-earnings-growth ratio of 1.37 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.91 by $0.56. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.22 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Wednesday, May 20th were given a $0.94 dividend. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on REGN shares. Royal Bank Of Canada decreased their price objective on Regeneron Pharmaceuticals from $762.00 to $707.00 and set a “sector perform” rating for the company in a report on Monday, May 18th. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a report on Wednesday, April 8th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the company a “buy” rating in a research report on Friday, May 1st. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $792.65.

View Our Latest Analysis on REGN

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.